b. subtilis

Dyclonine hydrochloride (Dyclonine HCl) 是润喉片的有效成分，具有显著的杀菌和杀真菌作用。

Roseoflavin 是天然色素，起初分离自Streptomyces davawensis。Roseoflavin 是核黄素和黄素单核苷酸的抗代谢类似物，显示出抗菌活性。

Pachybasin 是一种蒽醌真菌代谢物。 Pachybasin 对大肠杆菌、枯草芽孢杆菌、M. luteus、S. cerevisiae、C. albicans、A. niger 和 A. flavus 具有抗菌活性，MIC 值为 64.0 μg mL，对金黄色葡萄球菌具有抗菌活性 和尖孢镰刀菌，MIC 值分别为 32.0 和 16.0 μg mL。

Antimicrobial Compound 1 是一种烷基吡啶鎓化合物，尾部为 12C，头部为 4-羧基。 Antimicrobial Compound 1 对枯草芽孢杆菌和大肠杆菌具有抗菌活性。

4-Methylherniarin (7-Methoxy-4-methylcoumarin) 可荧光标记，是香豆素衍生物，具有抗革兰氏阳性和革兰氏阴性细菌染色的活性。它对B. subtilis 和S.sonnei 有活性，IC50值为 11.76 μg ml 和 13.47 μg ml。

o-Phenanthroline monohydrate (1, 10-Phenanthroline monohydrate) 是一种金属螯合剂，能够与 Fe2+形成红色螯合物，λmax为 510 nm，可防止链脲佐菌素诱导染色体畸变。它也是一种 MMP 的抑制剂。

NSC 55655 (5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione) 具有抗菌和抗氧化活性，抑制 B. subtilis, S. aureus, K. pneumonia, E. coli, S. typhi ，A. niger 和 C. albicans 的增殖，可用于糖尿病。

CCR-11 是一种具有抗菌活性的绕丹宁衍生物。 CCR-11 可以抑制 B. subtilis细胞和 HeLa 细胞增殖。 CCR-11 通过抑制 FtsZ 的组装和 GTPase 活性来抑制细菌增殖和细菌胞质分裂。 CCR-11 具有潜在的抗肿瘤活性，可用于研究乳腺癌和小儿骨髓增生异常。

Thiocillin I is a thiopeptide antibiotic and has in vitro antibacterial activity against Gram-positive bacterial strains(MIC of Thiocillin I against S. aureus 1974149, E. faecalis 1674621, B. subtilis ATCC 6633 and S. pyogenes 1744264 are 2 μg mL, 0.5 μg mL, 4 μg mL and 0.5 μg mL, respectively).

MRSA antibiotic 2 属于抗生素，对多种革兰氏阳性细菌具有活性，包括 B. subtilis、S. aureus 和耐甲氧西林的 S. aureus。

FtsZ-IN-12 (Compound 16e) 是一种抑制 filamentous temperature-sensitive mutant Z (FtsZ) 的化合物，能够促进 FtsZ 蛋白的聚合并抑制其 GTPase 活性，从而干扰细菌细胞分裂。FtsZ-IN-12 展现广谱抗菌活性，可抑制 B. subtilis ATCC9372、B. pumilus CMCC63202、S. aureus ATCC25923、E. coli BW25113 和 A. baumannii ATCC19606，MIC 为 0.062-1 µg mL。它能阻止细菌生物膜的形成，并消除成熟生物膜。同时，FtsZ-IN-12 具有杀菌活性，对哺乳动物红细胞无溶血毒性（15 mg kg）。

Antiangiogenic agent 8 (Compound 3m) 是一种抑菌剂，并具有抗血管生成活性。其对E. coli、P. aeruginosa、B. subtilis、S. aureus、C. glabrata的MIC分别为16、8、4、16、8 μg mL，MBC范围为32-64 μg mL。Antiangiogenic agent 8 可能在抗感染和心血管疾病研究中具有应用潜力。

Florfenicol-propanoate-piperidin (Compound 1) 是 Florfenicol 的一种衍生物，展示了抗菌活性。它能够抑制 E. coli ATCC25922、Salmonella CICC110420、S. aureus ATCC29213、B. subtilis CMCC(B)63501、E. faecalis ATCC29212、S. suis CVCC606 和 Haemophilus parasuis，最低抑制浓度（MIC）为 2-8 μM。

UCM05 (G28UCM) (G28UCM) 是一种有效的脂肪酸合酶 (FASN) 抑制剂，对 HER2+ 乳腺癌异种移植物具有作用活性，且在抗 HER2 耐药细胞系中具有活性。UCM05 是一种丝状温度敏感蛋白 Z (FtsZ) 抑制剂，可抑制革兰氏阳性菌B. subtilis 生长，MIC 值为 100 μM，但对革兰氏阴性菌E. coli 缺乏活性。

Netzahualcoyone inhibited the respiration of intact cells of B. subtilis but had no effect on the respiration of E. coli.

AN0128 （CRM-0005）是一种具有抗炎活性的含硼抗菌剂，抑制 S. aureus，S. epidermidis，P. acnes，B. subtilis，通过抑制 p38 MAP 激酶信号转导途径抑制巨噬细胞系中促炎细胞因子的产生，可用于皮肤病的研究。

Frequentin, an antibiotic originally isolated from P. frequentans, is active against bacteria (MICs = 200 and 300 µg ml for B. subtilis and S. aureus, respectively) and fungi.

Violacein is a bacterial metabolite originally isolated from C. violaceum that has antibacterial and antiprotozoal activities.[1] [2] It is produced by C. violaceum as a purple pigment in response to N-hexanoyl homoserine lactone , a property that has been modified to create a strain of C. violaceum used in detecting quorum-sensing molecules.[3] Violacein is active against Gram-positive bacteria, including B. subtilis and S. aureus (MICs = 0.8 and 1.6 µM, respectively). It is also active against P. falciparum, including chloroquine-susceptible and -resistant strains (IC50s = 0.85 and 0.63 µM, respectively).[2] It reduces parasitemia in a mouse model of nonlethal P. chabaudi chabaudi infection when administered at a dose of 7.5 mg/kg and increases survival in a mouse model of lethal P. chabaudi chabaudi infection. Violacein permeabilizes the cytoplasmic membrane of bacterial cells but does not affect the cell wall.[1]

Flumequine-13C3is intended for use as an internal standard for the quantification of flumequine by GC- or LC-MS. Flumequine is a fluoroquinolone antibiotic.1It is active againstS. aureus, S. pyogenes, B. subtilis, E. coli, P. aeruginosa, S. faecalis, andK. pneumoniae(MICs = 1-100 μg ml). Flumequine is also active against field isolates of B. hyodysenteriae (MICs = 6.25-200 μg ml).2It inhibits DNA gyrase, disrupting supercoiling of bacterial DNA to block transcription and replication.3In vivo, flumequine (50 mg kg) increases survival in rat models ofP. vulgaris-induced urinary tract infection andP. mirabilis-induced prostatitis.1Formulations containing flumequine have been used in the treatment of urinary tract infections in veterinary medicine. 1.Rohlfing, S.R., Gerster, J.R., and Kvam, D.C.Bioevaluation of the antibacterial flumequine for urinary tract useAntimicrob. Agents Chemother.10(1)20-24(1976) 2.Aller-Morán, L.M., Martínez-Lobo, F.J., Rubio, P., et al.Evaluation of the in vitro activity of flumequine against field isolates of Brachyspira hyodysenteriaeRes. Vet. Sci.10351-53(2015) 3.Smith, J.T.The mode of action of 4-quinolones and possible mechanisms of resistanceJ. Antimicrob. Chemother.18 (Suppl. D)21-29(1986)

Deoxyviolacein is a bacterial metabolite and byproduct in the biosynthesis of the bisindole alkaloid violacein that has anticancer, antibacterial, and antifungal properties. It inhibits proliferation of hepatocellular carcinoma cells when used at concentrations ranging from 0.1 to 1 μM. Deoxyviolacein (125 μg ml) has antibacterial activity against Gram-positive bacteria, including S. aureus, B. subtilis, and B. megaterium. It also has antifungal activity against R. solani when used at a concentration of 2 mg ml.

17-hydroxy Venturicidin A is a macrolide fungal metabolite originally isolated from Streptomyces. It has antibiotic activity against M. luteus, B. subtilis, and S. aureus and antifungal activity against V. dahlia, Fusarium, and C. tropicalis in a disc assay.

Linearmycin A is a polyene antibiotic that has been found inStreptomyces.1It is active against the bacteriaS. aureusandE. coli(MICs = 3.1 and 1.6 μg disc, respectively), the fungiS. cerevisiaeandC. albicans(MICs = 0.1 and 1.6 μg disc, respectively), and the plant pathogenic fungusA. nigerin disc assays (MIC = 0.2 μg disc). Linearmycin A induces lysis and degradation ofB. subtilisas a component ofStreptomycesMg1 extract.2 1.Sakuda, S., Guce-Bigol, U., Itoh, M., et al.Novel linear polyene antibiotics: LinearmycinsJ. Chem. Soc., Perkin Trans. 1182315-2319(1996) 2.Stubbendieck, R.M., and Straight, P.D.Escape from lethal bacterial competition through coupled activation of antibiotic resistance and a mobilized subpopulationPLoS Genet.11(12)e1005722(2015)

Thiocoraline is a depsipeptide and DNAbis-intercalator originally isolated fromMicromonosporawith antibacterial and anticancer activities.1,2It is active against the Gram-positive bacteriaS. aureus,B. subtilis, andM. luteus(MICs = 0.05, 0.05, and 0.03 μg ml, respectively) but not Gram-negativeE. coli,K. pneumoniae, orP. aeruginosa(MICs = >100 μg ml for all).1Thiocoraline inhibits RNA and DNA polymerase and thymidylate synthase (IC50s = 6, 6, and 15 μg ml, respectively), as well as RNA and DNA synthesisin vitro(IC50s = 0.008 and 0.4 μg ml, respectively). It is cytotoxic to P388, A549, HT-29, and MEL-28 cancer cells (IC50s = 0.002, 0.002, 0.01, and 0.002 μg ml, respectively). 1.Romero, F., Espilego, F., Pérez Baz, J., et al.Thiocoraline, a new depsipeptide with antitumor activity produced by a marine Micromonospora. I. Taxonomy, fermentation, isolation, and biological activitiesJ. Antibiot. (Tokyo)50(9)734-737(1997) 2.Negri, A., Marco, E., García-Hernández, V., et al.Antitumor activity, X-ray crystal structure, and DNA binding properties of thiocoraline A, a natural bisintercalating thiodepsipeptideJ. Med. Chem.50(14)3322-3333(2007)

Neospiramycin I is a macrolide antibiotic and derivative of spiramycin I.1It is active against the macrolide-sensitive KB210, but not the macrolide-resistant KB224, strain ofS. aureus(MICs = 3.12 and >100 μg/ml, respectively), as well asB. cereus,B. subtilis,M. luteus,E. coli, andK. pneumoniae(MICs = 1.56, 3.12, 3.12, 0.2, 50, and 12.5 μg/ml, respectively). Neospiramycin I binds toE. coliribosomes with an IC50value of 1.2 μM. It protects against mortality in a mouse model ofS. pneumoniaetype III infection (ED50= 399.8 mg/kg).2